GNCA Genocea Biosciences Inc.

2.16
-0.09  -4%
Previous Close 2.25
Open 2.27
Price To Book 1.85
Market Cap 56,483,328
Shares 26,149,689
Volume 78,311
Short Ratio
Av. Daily Volume 117,366
Stock charts supplied by TradingView

NewsSee all news

  1. Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors

    Entrepreneurial leader brings expertise growing biotech platform companies as former CEO of Editas Medicine and Avila Therapeutics Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new

  2. Genocea to Present at the Stifel 2019 Healthcare Conference

    CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president

  3. Genocea Preclinical Data at SITC Demonstrate that Inhibitory Neoantigens in an Otherwise Protective Vaccine Reverse Anti-Tumor Responses

    ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccination Inhibitory T cell responses exacerbate tumor growth CAMBRIDGE, Mass., Nov. 09, 2019 (GLOBE

  4. Genocea Presents Preclinical Research that Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses at Society for Immunotherapy of Cancer (SITC)

        Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapy Confirm positive GEN-009 clinical immunogenicity results

  5. Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference

    Additional positive GEN-009 clinical immunogenicity data driven by ATLAS™ to be presented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Announced September 25, 2017 that development will be ceased.
GEN-003
Genital herpes
Topline data did not meet endpoints - September 2015
GEN-004
Universal vaccine candidate against pneumococcus
Phase 1/2 data due mid-2020
GEN-009 vaccine
Various cancers

Latest News

  1. Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors

    Entrepreneurial leader brings expertise growing biotech platform companies as former CEO of Editas Medicine and Avila Therapeutics Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new

  2. Genocea to Present at the Stifel 2019 Healthcare Conference

    CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president

  3. Genocea Preclinical Data at SITC Demonstrate that Inhibitory Neoantigens in an Otherwise Protective Vaccine Reverse Anti-Tumor Responses

    ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccination Inhibitory T cell responses exacerbate tumor growth CAMBRIDGE, Mass., Nov. 09, 2019 (GLOBE

  4. Genocea Presents Preclinical Research that Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses at Society for Immunotherapy of Cancer (SITC)

        Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapy Confirm positive GEN-009 clinical immunogenicity results

  5. Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference

    Additional positive GEN-009 clinical immunogenicity data driven by ATLAS™ to be presented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE

  6. Genocea to Present at September Healthcare Conferences

    CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and